The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
 
Robin Jones
Consulting or Advisory Role - Adaptimmune; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; PharmaMar; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Neal Chawla
No Relationships to Disclose
 
Steven Attia
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; GlaxoSmithKline (Inst); Guardant Health; InhibRx (Inst); Intensity Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Noxopharm (Inst); PharmaMar (Inst); Philogen (Inst); Polaris (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Shanghai Pharma (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Seth Pollack
No Relationships to Disclose
 
Lee Cranmer
Consulting or Advisory Role - SpringWorks Therapeutics
Research Funding - AADi; AADi (Inst); Advenchen Laboratories (Inst); Avacta Life Sciences (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); InhibRx (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Philogen (Inst); Salarius Pharmaceuticals (Inst); Salarius Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Mahesh Seetharam
No Relationships to Disclose
 
Melissa Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Research Funding - Merck
 
Bartosz Chmielowski
Consulting or Advisory Role - Atreca; Regeneron; SERVIER; SpringWorks Therapeutics; Treeline Biosciences
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); AskGene Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); immatics (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Krystal Biotech (Inst); Macrogenics (Inst); Nested Therapeutics (Inst); Pierre Fabre (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - immatics
 
Brittany Siontis
Consulting or Advisory Role - Deciphera (Inst); Ratio (Inst)
 
Jonathan Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Breelyn Wilky
Consulting or Advisory Role - AADi; Adcendo; Boehringer Ingelheim; Deciphera; Epizyme; InhibRx; Polaris; SpringWorks Therapeutics
Research Funding - Exelixis
Travel, Accommodations, Expenses - Agenus
 
Nam Bui
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Checkpoint Capital; EcoR1 Capital; Immunome; Rain Therapeutics; SpringWorks Therapeutics
Research Funding - SpringWorks Therapeutics
 
Rashmi Chugh
Consulting or Advisory Role - Deciphera; InhibRx; Recordati; SpringWorks Therapeutics
Research Funding - Adaptimmune; Astex Pharmaceuticals (Inst); Ayala Pharmaceuticals (Inst); Cogent Biosciences (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Kronos Bio (Inst); Pfizer (Inst); PharmaMar (Inst); Polaris (Inst); PTC Therapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
Expert Testimony - Reminger Co, LPA
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Boehringer Ingelheim; Deciphera; Ipsen; Replimune
Research Funding - Advenc (Inst); Ascentage Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); IDRx (Inst); Karyopharm Therapeutics (Inst)
 
Brian Van Tine
Leadership - Polaris
Honoraria - Beijing Biostar Pharmaceuticals Co., Ltd.; Oncology Education; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; Adaptimmune; Advenchen Laboratories; Boxer Capital LLC; Crisper Therapeutics; Daiihi Sankyo; Deciphera; Galapagos NV; Hinge Bio; Kronos Bio, Inc.; Putnam Associates; Salarius Pharmaceuticals, INc.; Syneos Health
Research Funding - Polaris
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Sant Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma